JPRN-C000000131已完成2 期
Phase II study of irinotecan and amrubicin for relapsed non-small-cell lung cancer - Irinotecan and amrubicin for relapsed non-small-cell lung cance
Okayama Lung Cancer Study Group0 个研究点目标入组 30 人开始时间: 2005年9月12日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
Combination chemotherapy with irinotecan and amrubicin is effective in patients with NSCLC but showed moderate toxicities in second- or third-line settings.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Active concomitant malignancy Active Interstitial pneumonia Massive effusions Unstable angina, recent myocardial infarction Uncontrolled diabetes Severe active infection Other severe complications Pregnant or lactating women Inappropriate condition for this study judged by physicians.
研究者
相似试验
终止
2 期
Study of Irinotecan & Capecitabine in Metastatic Colorectal CancerSecondaryDrug Therapy, CombinationColorectal NeoplasmsNCT00506168National Cancer Center, Korea37
已完成
1 期
Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung CancerLung CancerNCT00132054Japan Multinational Trial Organization30
已完成
不适用
Phase II trial of irinotecan, paclitaxel plus bevacizumab for previously untreated patients with non-squamous and non-small cell lung cancer, detected the over-expression of ERCC1 by EBUS-GS.non-small cell lung cancerJPRN-UMIN000006514agasaki Thoracic Oncology Group12
已完成
2 期
Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung CancerLung CancerNCT00182806Roswell Park Cancer Institute38
已完成
2 期
Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung CancerLung CancerNCT00469898Vanderbilt-Ingram Cancer Center50